RU2014148136A - Композиции т-клеток с недостаточностью рецепторов т-клеток - Google Patents
Композиции т-клеток с недостаточностью рецепторов т-клеток Download PDFInfo
- Publication number
- RU2014148136A RU2014148136A RU2014148136A RU2014148136A RU2014148136A RU 2014148136 A RU2014148136 A RU 2014148136A RU 2014148136 A RU2014148136 A RU 2014148136A RU 2014148136 A RU2014148136 A RU 2014148136A RU 2014148136 A RU2014148136 A RU 2014148136A
- Authority
- RU
- Russia
- Prior art keywords
- processed
- nucleic acid
- zeta polypeptide
- cell
- seq
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 14
- 229920001184 polypeptide Polymers 0.000 claims abstract 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 14
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract 12
- 238000000034 method Methods 0.000 claims abstract 12
- 108020004707 nucleic acids Proteins 0.000 claims abstract 10
- 102000039446 nucleic acids Human genes 0.000 claims abstract 10
- 230000002950 deficient Effects 0.000 claims abstract 8
- 206010028980 Neoplasm Diseases 0.000 claims abstract 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract 4
- 210000004027 cell Anatomy 0.000 claims abstract 4
- 201000011510 cancer Diseases 0.000 claims abstract 2
- 108700010039 chimeric receptor Proteins 0.000 claims abstract 2
- 239000003112 inhibitor Substances 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 108090000623 proteins and genes Proteins 0.000 claims abstract 2
- 102000004169 proteins and genes Human genes 0.000 claims abstract 2
- 238000002560 therapeutic procedure Methods 0.000 claims abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
Abstract
1. Способ получения TCR-дефицитных Т-лимфоцитов, включающий введение в одну или более Т-клеток конструкции нуклеиновой кислоты, которая содержит нуклеиновую кислоту, кодирующую белок доминантно-негативного ингибитора, содержащий процессированный полипептид СОЗ-дзета.2. Способ по п. 1, отличающийся тем, что указанный процессированный полипептид CD3-дзета не содержит IT AM.3. Способ по п. 1, отличающийся тем, что указанная нуклеиновая кислота, кодирующая процессированный полипептид CD3-дзета, имеет SEQ ID №: 77 или 79.4. Способ по п. 1, отличающийся тем, что указанная нуклеиновая кислота, кодирующая процессированный полипептид CD3-дзета, содержит последовательность нуклеиновой кислоты SEQ ID №: 76 или 78.5. Способ по п. 1, отличающийся тем, что указанная Т-клетка дополнительно изменена таким образом, чтобы экспрессировать химерный рецептор, направленный против опухоли.6. TCR-дефицитная Т-клетка, полученная согласно любому из пп. 1-5.7. Фармацевтическая композиция, содержащая TCR-дефицитную Т-клетку согласно п. 6.8. Способ терапии, включающий введение субъекту, нуждающемуся в лечении, TCR-дефицитных Т-клеток или клеток согласно п. 6.9. Способ по п. 8, отличающийся тем, что указанный субъект, которого лечат, страдает раком.10. Вектор, содержащий нуклеиновую кислоту, кодирующую процессированный полипептид CD3-дзета согласно SEQ ID №: 77 или 79.11. Вектор по п. 10, отличающийся тем, что он содержит последовательность нуклеиновой кислоты, кодирующую процессированный полипептид CD3-дзета с последовательностью SEQ ID №: 76 или 78.12. Клетка, которая экспрессирует процессированный полипептид CD3-дзета с последовательностью SEQ ID №: 77 или 79.
Claims (12)
1. Способ получения TCR-дефицитных Т-лимфоцитов, включающий введение в одну или более Т-клеток конструкции нуклеиновой кислоты, которая содержит нуклеиновую кислоту, кодирующую белок доминантно-негативного ингибитора, содержащий процессированный полипептид СОЗ-дзета.
2. Способ по п. 1, отличающийся тем, что указанный процессированный полипептид CD3-дзета не содержит IT AM.
3. Способ по п. 1, отличающийся тем, что указанная нуклеиновая кислота, кодирующая процессированный полипептид CD3-дзета, имеет SEQ ID №: 77 или 79.
4. Способ по п. 1, отличающийся тем, что указанная нуклеиновая кислота, кодирующая процессированный полипептид CD3-дзета, содержит последовательность нуклеиновой кислоты SEQ ID №: 76 или 78.
5. Способ по п. 1, отличающийся тем, что указанная Т-клетка дополнительно изменена таким образом, чтобы экспрессировать химерный рецептор, направленный против опухоли.
6. TCR-дефицитная Т-клетка, полученная согласно любому из пп. 1-5.
7. Фармацевтическая композиция, содержащая TCR-дефицитную Т-клетку согласно п. 6.
8. Способ терапии, включающий введение субъекту, нуждающемуся в лечении, TCR-дефицитных Т-клеток или клеток согласно п. 6.
9. Способ по п. 8, отличающийся тем, что указанный субъект, которого лечат, страдает раком.
10. Вектор, содержащий нуклеиновую кислоту, кодирующую процессированный полипептид CD3-дзета согласно SEQ ID №: 77 или 79.
11. Вектор по п. 10, отличающийся тем, что он содержит последовательность нуклеиновой кислоты, кодирующую процессированный полипептид CD3-дзета с последовательностью SEQ ID №: 76 или 78.
12. Клетка, которая экспрессирует процессированный полипептид CD3-дзета с последовательностью SEQ ID №: 77 или 79.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/459,664 US9273283B2 (en) | 2009-10-29 | 2012-04-30 | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| US13/459,664 | 2012-04-30 | ||
| PCT/US2013/038921 WO2013166051A1 (en) | 2012-04-30 | 2013-04-30 | T cell receptor-deficient t cell compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018111729A Division RU2781979C2 (ru) | 2012-04-30 | 2013-04-30 | Композиции т-клеток с недостаточностью рецепторов т-клеток |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2014148136A true RU2014148136A (ru) | 2016-06-20 |
| RU2653761C2 RU2653761C2 (ru) | 2018-05-14 |
Family
ID=49515059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014148136A RU2653761C2 (ru) | 2012-04-30 | 2013-04-30 | Композиции т-клеток с недостаточностью рецепторов т-клеток |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9273283B2 (ru) |
| EP (3) | EP2844742B1 (ru) |
| JP (2) | JP6411328B2 (ru) |
| CN (3) | CN108384758B (ru) |
| AU (2) | AU2013256424B2 (ru) |
| BR (1) | BR112014027155B1 (ru) |
| CA (1) | CA2871955C (ru) |
| ES (2) | ES2711629T3 (ru) |
| HK (1) | HK1207882A1 (ru) |
| MX (2) | MX366018B (ru) |
| RU (1) | RU2653761C2 (ru) |
| WO (1) | WO2013166051A1 (ru) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7994298B2 (en) | 2004-09-24 | 2011-08-09 | Trustees Of Dartmouth College | Chimeric NK receptor and methods for treating cancer |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| US9833476B2 (en) | 2011-08-31 | 2017-12-05 | The Trustees Of Dartmouth College | NKP30 receptor targeted therapeutics |
| JP6389166B2 (ja) | 2012-05-07 | 2018-09-12 | トラスティーズ・オブ・ダートマス・カレッジ | 抗ｂ７−ｈ６抗体、融合タンパク質、及びこれらを使用する方法 |
| US9499855B2 (en) | 2013-03-14 | 2016-11-22 | Elwha Llc | Compositions, methods, and computer systems related to making and administering modified T cells |
| US9587237B2 (en) | 2013-03-14 | 2017-03-07 | Elwha Llc | Compositions, methods, and computer systems related to making and administering modified T cells |
| US9745368B2 (en) | 2013-03-15 | 2017-08-29 | The Trustees Of The University Of Pennsylvania | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| AU2014351871B2 (en) * | 2013-11-22 | 2020-02-13 | Cellectis | Method for generating batches of allogeneic T-cells with averaged potency |
| WO2015090229A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
| CA2961636A1 (en) | 2014-09-17 | 2016-03-24 | Boris ENGELS | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| EP3215166B1 (en) | 2014-10-31 | 2024-04-24 | The Trustees of the University of Pennsylvania | Altering gene expression in car-t cells and uses thereof |
| SG10202103475XA (en) * | 2014-12-02 | 2021-05-28 | Prospect Chartercare Rwmc Llc | Methods and compositons for treating cancer |
| US10273300B2 (en) | 2014-12-29 | 2019-04-30 | The Trustees Of The University Of Pennsylvania | Methods of making chimeric antigen receptor-expressing cells |
| RS63574B1 (sr) * | 2015-02-06 | 2022-10-31 | Nat Univ Singapore | Metode za povećanje efikasnosti imuno ćelija |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| KR20220167337A (ko) | 2015-03-27 | 2022-12-20 | 이매틱스 바이오테크놀로지스 게엠베하 | 다양한 종양에 대한 면역요법에서의 사용을 위한 펩티드 및 펩티드의 조합 |
| WO2016168595A1 (en) | 2015-04-17 | 2016-10-20 | Barrett David Maxwell | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| EP3294342A4 (en) | 2015-05-08 | 2018-11-07 | President and Fellows of Harvard College | Universal donor stem cells and related methods |
| AU2016297014B2 (en) * | 2015-07-21 | 2021-06-17 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| CN109824778B (zh) * | 2015-09-18 | 2022-07-19 | 上海科济制药有限公司 | 抗cd19全人抗体以及靶向cd19的免疫效应细胞 |
| AU2016342041B2 (en) * | 2015-10-23 | 2021-12-02 | Eureka Therapeutics, Inc. | Antibody/T-cell receptor chimeric constructs and uses thereof |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| MA45478A (fr) * | 2016-04-11 | 2019-02-20 | Arbutus Biopharma Corp | Compositions de conjugués d'acides nucléiques ciblés |
| EP4180519A1 (en) | 2016-04-15 | 2023-05-17 | Memorial Sloan Kettering Cancer Center | Transgenic t cell and chimeric antigen receptor t cell compositions and related methods |
| KR102428530B1 (ko) | 2016-05-05 | 2022-08-02 | 사우스웨스트 리서치 인스티튜트 | 세포 확장을 위한 3차원 생물 반응기 및 관련 적용 |
| CA2937157A1 (en) | 2016-07-25 | 2018-01-25 | Ucl Business Plc | Protein-based t-cell receptor knockdown |
| US11298408B2 (en) | 2016-09-09 | 2022-04-12 | The Feinstein Institutes For Medical Research | Methods of treating hypertension |
| MX2019003768A (es) | 2016-10-03 | 2019-06-24 | Juno Therapeutics Inc | Moleculas de enlace especificas de hpv. |
| CA3039774A1 (en) * | 2016-10-10 | 2018-04-19 | The National Institute for Biotechnology in the Negev Ltd. | Non-cytotoxic modified cells and use thereof |
| US10550183B2 (en) | 2016-11-22 | 2020-02-04 | National University Of Singapore | Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies |
| US11649288B2 (en) | 2017-02-07 | 2023-05-16 | Seattle Children's Hospital | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| CA3054621A1 (en) | 2017-03-22 | 2018-09-27 | Novartis Ag | Compositions and methods for immunooncology |
| KR20190142775A (ko) | 2017-04-19 | 2019-12-27 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 조작된 항원 수용체를 발현하는 면역 세포 |
| CN110741016A (zh) | 2017-04-26 | 2020-01-31 | 优瑞科生物技术公司 | 嵌合抗体/t-细胞受体构筑体及其用途 |
| EP3650545A4 (en) | 2017-06-20 | 2021-03-31 | Jiangsu Hengrui Medicine Co., Ltd. | METHOD OF INACTIVATION OF A TARGET GENE IN T CELLS IN VITRO AND ARNCR USED IN THE PROCESS |
| WO2019002633A1 (en) * | 2017-06-30 | 2019-01-03 | Cellectis | CELLULAR IMMUNOTHERAPY FOR REPETITIVE ADMINISTRATION |
| AU2018313939A1 (en) | 2017-08-10 | 2020-02-06 | National University Of Singapore | T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof |
| MX2020002901A (es) | 2017-09-19 | 2020-07-22 | Massachusetts Inst Technology | Composiciones para la terapia con celulas t con receptores de antigeno quimerico y usos de las mismas. |
| EP4215543A3 (en) | 2017-10-03 | 2023-10-11 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
| AU2018349093A1 (en) * | 2017-10-12 | 2020-05-28 | Mcmaster University | T cell-antigen coupler with Y182T mutation and methods and uses thereof |
| JP2021505208A (ja) * | 2017-12-05 | 2021-02-18 | セリアド エス．アー．Ｃｅｌｙａｄ Ｓ．Ａ． | 養子細胞療法用細胞の持続性を向上するための組成物および方法 |
| JP2021505207A (ja) * | 2017-12-05 | 2021-02-18 | セリアド エス．アー．Ｃｅｌｙａｄ Ｓ．Ａ． | Ｎｋｇ２ｄベースの受容体を発現する免疫細胞のフラトリサイドの減少 |
| WO2019118508A1 (en) | 2017-12-12 | 2019-06-20 | The Trustees Of The University Of Pennsylvania | Genetically modified immune cells targeting ny-eso-1 and methods of use thereof |
| WO2019133969A2 (en) * | 2017-12-29 | 2019-07-04 | Memorial Sloan-Kettering Cancer Center | Enhanced chimeric antigen receptors and uses thereof |
| US11311576B2 (en) | 2018-01-22 | 2022-04-26 | Seattle Children's Hospital | Methods of use for CAR T cells |
| US11149244B2 (en) | 2018-04-04 | 2021-10-19 | Southwest Research Institute | Three-dimensional bioreactor for T-cell activation and expansion for immunotherapy |
| EP3773908A1 (en) | 2018-04-05 | 2021-02-17 | Juno Therapeutics, Inc. | T cell receptors and engineered cells expressing same |
| CN112262214A (zh) * | 2018-04-12 | 2021-01-22 | 优莫佳生物制药股份有限公司 | 病毒载体及包装细胞系 |
| EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| CN110616188B (zh) * | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种通用型car-t细胞及其制备方法和应用 |
| CA3103337A1 (en) * | 2018-07-26 | 2020-01-30 | Nanjing Legend Biotech Co., Ltd. | Nef-containing t cells and methods of producing thereof |
| SG11202102986XA (en) | 2018-09-24 | 2021-04-29 | Southwest Res Inst | Three-dimensional bioreactors |
| KR20210068478A (ko) | 2018-09-28 | 2021-06-09 | 메사추세츠 인스티튜트 오브 테크놀로지 | 콜라겐-국재화된 면역조정성 분자 및 그의 방법 |
| CN111788302A (zh) * | 2018-11-21 | 2020-10-16 | 南京北恒生物科技有限公司 | 修饰的t细胞及其用途 |
| EP3894011A1 (en) | 2018-12-11 | 2021-10-20 | Obsidian Therapeutics, Inc. | Membrane bound il12 compositions and methods for tunable regulation |
| CN111378624B (zh) * | 2018-12-29 | 2023-10-20 | 深圳市第三人民医院 | 一种靶向性抗肿瘤t细胞及其制备方法和应用 |
| JP2022524081A (ja) | 2019-03-08 | 2022-04-27 | オブシディアン セラピューティクス， インコーポレイテッド | 調整可能な制御のためのヒトカルボニックアンヒドラーゼ２組成物及び方法 |
| EP3733707A1 (en) | 2019-04-30 | 2020-11-04 | Celyad S.A. | Car t-cells targeting bcma and uses thereof |
| EP3983538A1 (en) | 2019-06-12 | 2022-04-20 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| WO2020252404A1 (en) | 2019-06-12 | 2020-12-17 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| US11642409B2 (en) | 2019-06-26 | 2023-05-09 | Massachusetts Insttute of Technology | Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof |
| US20230092895A1 (en) | 2019-08-30 | 2023-03-23 | Obsidian Therapeutics, Inc. | Tandem cd19 car-based compositions and methods for immunotherapy |
| EP4087861A1 (en) | 2020-01-08 | 2022-11-16 | Obsidian Therapeutics, Inc. | Compositions and methods for tunable regulation of transcription |
| MX2022008648A (es) | 2020-01-23 | 2022-12-15 | The Children´S Medical Center Corp | Diferenciacion de celulas t sin estroma a partir de celulas madre pluripotentes humanas. |
| US11896619B2 (en) | 2020-03-10 | 2024-02-13 | Massachusetts Institute Of Technology | Compositions and methods for immunotherapy of NPM1c-positive cancer |
| IL296242A (en) | 2020-03-10 | 2022-11-01 | Massachusetts Inst Technology | Methods for producing engineered memory-like nk cells and preparations containing them |
| WO2021221782A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Chimeric antigen receptor-targeting ligands and uses thereof |
| WO2021221783A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof |
| WO2022005462A1 (en) * | 2020-06-30 | 2022-01-06 | Tr1X, Inc. | Poly-donor cd4+ t cells expressing il-10 and uses thereof |
| JP2024509853A (ja) | 2021-03-03 | 2024-03-05 | ジュノー セラピューティクス インコーポレイテッド | Ｔ細胞療法およびｄｇｋ阻害剤の組合せ |
| WO2023081715A1 (en) | 2021-11-03 | 2023-05-11 | Viracta Therapeutics, Inc. | Combination of car t-cell therapy with btk inhibitors and methods of use thereof |
| WO2023201133A1 (en) | 2022-04-14 | 2023-10-19 | Board Of Regents Of The University Of Nebraska | Cell therapy for alzheimer's disease |
| WO2024054944A1 (en) | 2022-09-08 | 2024-03-14 | Juno Therapeutics, Inc. | Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing |
Family Cites Families (158)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6242567B1 (en) | 1984-07-27 | 2001-06-05 | City Of Hope | Method for detection and prevention of human cytomegalovirus infection |
| US6133433A (en) | 1984-07-27 | 2000-10-17 | City Of Hope | Method for detection and prevention of human cytomegalovirus infection |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US5667967A (en) | 1990-05-01 | 1997-09-16 | The Board Of Trustees Of The Leland Stanford Junior University | T-cell receptor varible transcripts as disease related markers |
| IL86278A (en) | 1988-05-04 | 2003-06-24 | Yeda Res & Dev | Endowing cells with antibody specificity using chimeric t cell receptor |
| US6464978B1 (en) | 1989-03-21 | 2002-10-15 | The Immune Response Corporation | Vaccination and methods against multiple sclerosis resulting from pathogenic responses by specific T cell populations |
| US5415874A (en) | 1989-10-31 | 1995-05-16 | The Board Of Trustees Of The Leland Stanford Junior University | Natural killer cell lines and clones with antigen specificity |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US6416971B1 (en) | 1990-05-15 | 2002-07-09 | E.R. Squibb & Sons, Inc. | Soluble single chain T cell receptors |
| US6407221B1 (en) | 1990-12-14 | 2002-06-18 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| DE69123241T2 (de) | 1990-12-14 | 1997-04-17 | Cell Genesys Inc | Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen |
| FR2672901B1 (fr) | 1991-02-15 | 1994-09-30 | Immunotech Sa | Nouvelles molecules de dna recombinants codant pour une chaine du recepteur pour l'antigene des cellules t, procede de preparation, anticorps et medicaments les renfermant. |
| US5851828A (en) | 1991-03-07 | 1998-12-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
| IE920716A1 (en) * | 1991-03-07 | 1992-09-09 | Gen Hospital Corp | Redirection of cellular immunity by receptor chimeras |
| US6753162B1 (en) | 1991-03-07 | 2004-06-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
| US7049136B2 (en) | 1991-03-07 | 2006-05-23 | The General Hospital Corporation | Redirection of cellular immunity by receptor chimeras |
| JP3238447B2 (ja) | 1991-12-31 | 2001-12-17 | 株式会社エスアールエル | ヒト白血球株化細胞 |
| US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
| US6172278B1 (en) * | 1992-09-14 | 2001-01-09 | The General Hospital Corporation | Ikaros transgenic cells and mice |
| DK0692026T3 (da) | 1993-04-09 | 1999-09-27 | Pfizer | En human T-cellereceptor fra den G-proteinkoblede receptorfamilie |
| US5419900A (en) | 1993-05-19 | 1995-05-30 | The United States Of America As Represented By The Department Of Of Health And Human Services | Immunologic enhancement with intermittent interleukin-2 therapy |
| US5552300A (en) | 1994-01-13 | 1996-09-03 | T Cell Sciences, Inc. | T cell antigen receptor V region proteins and methods of preparation thereof |
| DE4408999A1 (de) | 1994-03-16 | 1995-09-28 | Braun Melsungen Ag | Humane T-Zellrezeptoren zur diagnostischen sowie therapeutischen Verwendung bei autoimmunem Diabetes mellitus |
| CA2188422C (en) | 1994-05-02 | 2011-03-15 | Bernd Groner | Bifunctional protein, preparation and use |
| WO1996013584A1 (en) | 1994-11-01 | 1996-05-09 | Targeted Genetics Corporation | Chimeric receptors for the generation of selectively-activatable th-independent cytotoxic t cells |
| GB9423085D0 (en) | 1994-11-16 | 1995-01-04 | Stringer Bradley M J | Targeted T lymphocytes |
| US5712149A (en) | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
| US6103521A (en) | 1995-02-06 | 2000-08-15 | Cell Genesys, Inc. | Multispecific chimeric receptors |
| HU225688B1 (en) | 1995-02-24 | 2007-06-28 | Gen Hospital Corp | Redirection of cellular immunity by receptor chimeras |
| US5830755A (en) | 1995-03-27 | 1998-11-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | T-cell receptors and their use in therapeutic and diagnostic methods |
| DE19540515C1 (de) | 1995-10-31 | 1997-02-06 | Boehringer Ingelheim Int | Tumortherapie durch adoptiven Transfer CD44v-spezifischer zytotoxischer T-Lymphozyten |
| GB9526131D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Recombinant chimeric receptors |
| CA2246333A1 (en) | 1996-03-05 | 1997-09-12 | The Scripps Research Institute | Recombinant constructs encoding t cell receptors specific for human hla-restricted tumor antigens |
| DE19625191A1 (de) | 1996-06-24 | 1998-01-02 | Boehringer Mannheim Gmbh | Nierenkarzinom-spezifische T-Zellen |
| EP0937095A4 (en) | 1996-10-25 | 1999-12-22 | Cell Genesys Inc | TARGETED CYTOLYSIS OF CANCER CELLS |
| US20040038894A1 (en) * | 1996-12-31 | 2004-02-26 | Institut National De La Sante Et De La Recherche Medicale (I.N.S.E.R.M.) | Compounds for modulating cell negative regulations and biological applications thereof |
| AU6537798A (en) | 1997-03-14 | 1998-10-12 | Denise Casentini-Borocz | Targeted cytolysis of cancer cells |
| US20030060444A1 (en) | 1997-06-25 | 2003-03-27 | Celltech Therapeutics, Ltd. | Cell activation process and reagents therefor |
| US6759243B2 (en) | 1998-01-20 | 2004-07-06 | Board Of Trustees Of The University Of Illinois | High affinity TCR proteins and methods |
| GB9809658D0 (en) | 1998-05-06 | 1998-07-01 | Celltech Therapeutics Ltd | Biological products |
| WO2000014257A1 (en) | 1998-09-04 | 2000-03-16 | Sloan-Kettering Institute For Cancer Research | Fusion receptors specific for prostate-specific membrane antigen and uses thereof |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| IL127142A0 (en) | 1998-11-19 | 1999-09-22 | Yeda Res & Dev | Immune cells having predefined biological specificity |
| CA2357035A1 (en) | 1998-12-29 | 2000-07-06 | University Of Vermont And State Agricultural College | Use of cd40 engagement to alter t cell receptor usage |
| JP2002541845A (ja) | 1999-04-16 | 2002-12-10 | セルテック セラピューティックス リミテッド | 合成膜貫通成分 |
| GB9925848D0 (en) | 1999-11-01 | 1999-12-29 | Celltech Therapeutics Ltd | Biological products |
| EP1118661A1 (en) | 2000-01-13 | 2001-07-25 | Het Nederlands Kanker Instituut | T cell receptor libraries |
| US6770749B2 (en) | 2000-02-22 | 2004-08-03 | City Of Hope | P53-specific T cell receptor for adoptive immunotherapy |
| IL136459A0 (en) | 2000-05-30 | 2001-06-14 | Galim Galil Immunology Ltd | Antibody library |
| US6953576B2 (en) | 2000-08-21 | 2005-10-11 | University Health Network | Method of modulating tumor immunity |
| EP1188825A1 (en) | 2000-09-18 | 2002-03-20 | Universiteit Leiden | T cell receptor transfer into a candidate effector cell or a precursor thereof |
| GB0025307D0 (en) | 2000-10-16 | 2000-11-29 | Celltech Chiroscience Ltd | Biological products |
| WO2002077029A2 (en) | 2000-11-07 | 2002-10-03 | City Of Hope | Cd19-specific redirected immune cells |
| US20030068616A1 (en) * | 2000-12-07 | 2003-04-10 | Hanan Polansky | Drug discovery assays based on microcompetition for a limiting GABP complex |
| US20030104358A1 (en) * | 2000-12-07 | 2003-06-05 | Hanan Polansky | Diagnosis methods based on microcompetition for a limiting GABP complex |
| US20030069199A1 (en) * | 2000-12-07 | 2003-04-10 | Hanan Polansky | Treatment methods based on microcompetition for a limiting GABP complex |
| DK1409646T3 (da) | 2000-12-19 | 2012-08-06 | Altor Bioscience Corp | Transgene dyr omfattende et humaniseret immunsystem |
| IL141539A0 (en) | 2001-02-20 | 2002-03-10 | Yeda Res & Dev | Dna molecules and cells transfected therewith |
| US20040115198A1 (en) | 2001-02-28 | 2004-06-17 | Fred Hutchinson Cancer Research Center | Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US7514537B2 (en) | 2001-04-30 | 2009-04-07 | City Of Hope | Chimeric immunoreceptor useful in treating human gliomas |
| DK1546188T3 (da) | 2001-06-05 | 2008-10-27 | Altor Bioscience Corp | P53-bindende T-cellereceptormolekyler og anvendelser deraf |
| CA2457143A1 (en) | 2001-08-17 | 2003-02-27 | Roger Williams Hospital | In situ immunization |
| US7939059B2 (en) | 2001-12-10 | 2011-05-10 | California Institute Of Technology | Method for the generation of antigen-specific lymphocytes |
| US20060269529A1 (en) | 2002-05-07 | 2006-11-30 | Niederman Thomas M | Modified t lymphocytes and uses therefor |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US20060247420A1 (en) | 2002-09-04 | 2006-11-02 | George Coukos | Immune cell recptor ligand and immune cell receptor |
| DE10244457A1 (de) | 2002-09-24 | 2004-04-01 | Johannes-Gutenberg-Universität Mainz | Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren |
| DE10259713A1 (de) | 2002-12-19 | 2004-07-08 | Johannes-Gutenberg-Universität Mainz | Verfahren zur Expressionsstabilisierung und Verbesserung der spezifischen Effektorfunktion von Einzelketten-Antigenerkennenden genetischen Konstrukten (scARC) und entsprechend mutierten MDM2-Protein spezifischen scT-Zell Rezeptoren |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| WO2005019420A2 (en) | 2003-08-20 | 2005-03-03 | St. Jude Children's Research Hospital | Chimeric receptors with disrupted dileucine motifs |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| US20050113564A1 (en) | 2003-11-05 | 2005-05-26 | St. Jude Children's Research Hospital | Chimeric receptors with 4-1BB stimulatory signaling domain |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| US20050238626A1 (en) | 2004-04-01 | 2005-10-27 | Lili Yang | Antigen specific T cell therapy |
| NZ550810A (en) | 2004-05-19 | 2009-05-31 | Immunocore Ltd | High affinity NY-ESO T cell receptor |
| NZ550815A (en) | 2004-05-19 | 2009-04-30 | Immunocore Ltd | Method of improving T cell receptors |
| JP5563194B2 (ja) | 2004-06-29 | 2014-07-30 | イムノコア リミテッド | 改変ｔ細胞レセプターを発現する細胞 |
| CA2572467A1 (en) * | 2004-07-01 | 2006-01-19 | Virxsys Corporation | Vector packaging cell line |
| PT2921500T (pt) | 2004-07-10 | 2023-09-25 | The Institute For Cancer Res | Linhas de células assassinas naturais humanas modificadas geneticamente |
| US7915036B2 (en) | 2004-09-13 | 2011-03-29 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compositions comprising T cell receptors and methods of use thereof |
| US7994298B2 (en) | 2004-09-24 | 2011-08-09 | Trustees Of Dartmouth College | Chimeric NK receptor and methods for treating cancer |
| WO2007044033A2 (en) | 2004-12-07 | 2007-04-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen |
| WO2006060878A1 (en) | 2004-12-10 | 2006-06-15 | Peter Maccallum Cancer Institute | Methods and compositions for adoptive immunotherapy |
| AU2006228308B2 (en) | 2005-04-01 | 2012-05-17 | Adaptimmune Limited | High affinity HIV T cell receptors |
| GB0524477D0 (en) | 2005-11-30 | 2006-01-11 | Avidex Ltd | Isolated T cell receptors which specifically bind to vygfvracl-hla-24 |
| GB0511124D0 (en) | 2005-06-01 | 2005-07-06 | Avidex Ltd | High affinity melan-a t cell receptors |
| JP2006345852A (ja) * | 2005-06-16 | 2006-12-28 | Virxsys Corp | 抗体複合体 |
| ES2672895T3 (es) | 2005-08-05 | 2018-06-18 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh | Generación de células T específicas de antígeno |
| US8003770B2 (en) | 2005-09-13 | 2011-08-23 | Mie University | T-cell receptor and nucleic acid encoding the receptor |
| EP1795599A1 (en) | 2005-12-09 | 2007-06-13 | Schuler, Gerold, Prof. Dr. | Methods for generating antigen-specific effector T cells |
| US7820174B2 (en) | 2006-02-24 | 2010-10-26 | The United States Of America As Represented By The Department Of Health And Human Services | T cell receptors and related materials and methods of use |
| ATE550356T1 (de) | 2006-05-03 | 2012-04-15 | Us Gov Health & Human Serv | Chimäre t-zellen-rezeptoren sowie entsprechende materialien und verwendungsverfahren |
| EP1870418A1 (en) | 2006-06-20 | 2007-12-26 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Allorestricted peptide-specific T cells |
| AT503861B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
| EP1878744A1 (en) | 2006-07-13 | 2008-01-16 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Epitope-tag for surface-expressed T-cell receptor proteins, uses thereof and method of selecting host cells expressing them |
| DE102006041455B4 (de) | 2006-09-04 | 2011-07-28 | Johannes-Gutenberg-Universität Mainz, 55122 | Verfahren zur Herstellung einer einen stabilisierten funktionellen humanen Einzelketten-Antigen-erkennenden-TCR (scTCR) exprimierenden Zelllinie, damit hergestellt Zelllinie, stabilisierter TAA-spezifischer scTCR, deren Verwendungen und diese enthaltende pharmazeutische Zusammmensetzungen |
| WO2008042814A2 (en) | 2006-09-29 | 2008-04-10 | California Institute Of Technology | Mart-1 t cell receptors |
| US20100105136A1 (en) | 2006-10-09 | 2010-04-29 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
| EP1932537A1 (en) | 2006-12-12 | 2008-06-18 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Expression of transgenic T cell receptors in LAK-T cells |
| US7508404B2 (en) | 2006-12-21 | 2009-03-24 | Eastman Kodak Company | Thermal printer with two print heads |
| US8216565B2 (en) | 2007-01-12 | 2012-07-10 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | GP100-specific T cell receptors and related materials and methods of use |
| WO2008095141A2 (en) | 2007-01-31 | 2008-08-07 | Yeda Research And Development Co. Ltd. | Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease |
| ES2529166T3 (es) | 2007-03-30 | 2015-02-17 | Memorial Sloan-Kettering Cancer Center | Expresión constitutiva de ligandos coestimuladores en linfocitos T transferidos de forma adoptiva |
| US20110213288A1 (en) * | 2007-04-23 | 2011-09-01 | The Board Of Regents, The University Of Texas System | Device And Method For Transfecting Cells For Therapeutic Uses |
| EP3031916B1 (en) | 2007-06-11 | 2017-06-07 | Takara Bio Inc. | Method for expression of specific gene |
| JP5496897B2 (ja) | 2007-10-04 | 2014-05-21 | ザイモジェネティクス， インコーポレイテッド | Ｂ７ファミリーメンバーのｚＢ７Ｈ６ならびに関連する組成物および方法 |
| GB0721686D0 (en) | 2007-11-05 | 2007-12-12 | Medinnova As | Polypeptides |
| WO2009091826A2 (en) | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| US20110280894A1 (en) | 2008-07-31 | 2011-11-17 | Angela Krackhardt | Her2/neu specific t cell receptors |
| PL3006459T3 (pl) | 2008-08-26 | 2022-01-17 | City Of Hope | Sposób i kompozycje dla wzmocnionego działania efektorowego komórek t przeciw guzowi nowotworowemu |
| US20110318380A1 (en) | 2008-10-01 | 2011-12-29 | Dako Denmark A/S | MHC Multimers in Cancer Vaccines and Immune Monitoring |
| WO2010054141A2 (en) | 2008-11-06 | 2010-05-14 | The Trustees Of Columbia University In The City Of New York | Polynucleotides encoding a human trim-cyp fusion polypeptide, compositions thereof, and methods of using same |
| EP2186825A1 (en) | 2008-11-13 | 2010-05-19 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Human-derived T cell receptors |
| AU2009317161B2 (en) | 2008-11-24 | 2014-09-11 | Helmholtz Zentrum Munchen Deutsches Forschungszentrum Fur Gesundheit Und Umwelt Gmbh | High affinity T cell receptor and use thereof |
| WO2010088160A1 (en) | 2009-01-28 | 2010-08-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors and related materials and methods of use |
| FR2941858B1 (fr) | 2009-02-10 | 2011-03-11 | Charam Khosrvaninejad | Dispositif chirurgical apte a realiser la protection temporaire d'une anastomose |
| WO2010107400A1 (en) | 2009-03-20 | 2010-09-23 | Agency For Science, Technology And Research | Genetically modified animal and method of obtaining the same |
| WO2010140862A2 (ko) * | 2009-06-05 | 2010-12-09 | Seol Dai-Wu | 단일 또는 멀티 표적 유전자를 억제하는 멀티-시스트로닉 ｓｈＲＮＡ 발현 카세트 |
| GB0911566D0 (en) | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| US10138276B2 (en) * | 2009-09-30 | 2018-11-27 | Signablok, Inc. | Inhibition of TCR signaling with peptide variants |
| US8465743B2 (en) | 2009-10-01 | 2013-06-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| CA2777053A1 (en) | 2009-10-06 | 2011-04-14 | The Board Of Trustees Of The University Of Illinois | Human single-chain t cell receptors |
| US9273283B2 (en) * | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| WO2011064664A2 (en) | 2009-11-24 | 2011-06-03 | Chrontech Pharma Ab | T cell receptors specific for immunodominant ctl epitopes of hcv |
| CA2783740C (en) | 2009-12-09 | 2020-03-10 | Institut National De La Sante Et De La Recherche Medicale | Monoclonal antibodies that bind b7h6 and uses thereof |
| WO2011085178A1 (en) | 2010-01-11 | 2011-07-14 | Trustees Of Dartmouth College | Monomeric bi-specific fusion protein |
| AU2011281062B2 (en) * | 2010-07-21 | 2015-01-22 | Board Of Regents, The University Of Texas System | Methods and compositions for modification of a HLA locus |
| CA2805320A1 (en) | 2010-07-28 | 2012-02-02 | Immunocore Ltd | T cell receptors |
| EP3467101A3 (en) | 2010-09-08 | 2019-06-19 | Baylor College of Medicine | Immunotherapy of brain tumor using geneticially engineered gd2-specific t cells |
| WO2012050374A2 (en) | 2010-10-13 | 2012-04-19 | Innocell, Inc. | Immunotherapy for solid tumors |
| KR20140002649A (ko) | 2010-10-27 | 2014-01-08 | 베이롤 칼리지 오브 메드신 | Ｃｄ７０－양성 악성 종양에 대해 ｔ 세포를 재지정하기 위한 키메라 ｃｄ２７ 수용체 |
| WO2012134813A1 (en) | 2011-03-31 | 2012-10-04 | St. Jude Children's Research Hospital | Methods and compositions for identifying minimal residual disease in acute lymphoblastic leukemia |
| US9833476B2 (en) * | 2011-08-31 | 2017-12-05 | The Trustees Of Dartmouth College | NKP30 receptor targeted therapeutics |
| WO2013074916A1 (en) * | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| RU2014129863A (ru) * | 2011-12-21 | 2016-02-10 | Модерна Терапьютикс, Инк. | Способы повышения жизнеспособности или увеличения продолжительности жизни органа или экспланта органа |
| MA37681B2 (fr) * | 2012-05-25 | 2020-07-29 | Cellectis | Procédés pour modifier des lymphocytes t résistants allogéniques et immunosuppresseurs pour l'immunothérapie |
| AU2014296059B2 (en) | 2013-08-02 | 2020-12-10 | The Regents Of The University Of California | Engineering antiviral T cell immunity through stem cells and chimeric antigen receptors |
| US10144770B2 (en) | 2013-10-17 | 2018-12-04 | National University Of Singapore | Chimeric receptors and uses thereof in immune therapy |
| EP3104866A4 (en) * | 2014-02-14 | 2017-08-02 | Bellicum Pharmaceuticals, Inc. | Methods for activating t cells using an inducible chimeric polypeptide |
| PL3298033T5 (pl) * | 2015-05-18 | 2023-10-30 | TCR2 Therapeutics Inc. | Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych |
| AU2016297014B2 (en) * | 2015-07-21 | 2021-06-17 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| CA3020848A1 (en) * | 2016-04-15 | 2017-10-19 | Janssen Pharmaceuticals, Inc. | Anti-human vista antibodies and use thereof |
| WO2017190100A1 (en) * | 2016-04-28 | 2017-11-02 | The Trustees Of Dartmouth College | Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof |
| SG11201908719QA (en) * | 2017-03-22 | 2019-10-30 | Novartis Ag | Biomarkers and car t cell therapies with enhanced efficacy |
| CA3065126A1 (en) * | 2017-06-01 | 2018-12-06 | Innovative Cellular Therapeutics CO., LTD. | Chimeric antigen receptor cell preparation and uses thereof |
| AU2018313939A1 (en) * | 2017-08-10 | 2020-02-06 | National University Of Singapore | T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof |
| EP3678669A4 (en) * | 2017-09-08 | 2021-06-09 | University Health Network | POLYTHERAPIES TO INHIBIT POLO-TYPE KINASE 4 |
| WO2019075385A1 (en) * | 2017-10-12 | 2019-04-18 | Board Of Regents, The University Of Texas System | T-LYMPHOCYTE COMPOSITIONS FOR IMMUNOTHERAPY |
| WO2019136273A1 (en) * | 2018-01-05 | 2019-07-11 | NantBio Inc. | Reprogrammed t cell-like nk cells |
| CA3103337A1 (en) * | 2018-07-26 | 2020-01-30 | Nanjing Legend Biotech Co., Ltd. | Nef-containing t cells and methods of producing thereof |
| CA3107675A1 (en) * | 2018-07-30 | 2020-02-06 | University Of Southern California | Improving the efficacy and safety of adoptive cellular therapies |
| JP2022511502A (ja) * | 2018-12-05 | 2022-01-31 | ジェネンテック， インコーポレイテッド | がんの免疫療法のための診断方法及び診断用組成物 |
| US11858977B2 (en) * | 2019-10-24 | 2024-01-02 | Innovative Cellular Therapeutics Holdings, Ltd. | Modified TCR and uses thereof |
-
2012
- 2012-04-30 US US13/459,664 patent/US9273283B2/en active Active
-
2013
- 2013-04-30 WO PCT/US2013/038921 patent/WO2013166051A1/en active Application Filing
- 2013-04-30 MX MX2014013118A patent/MX366018B/es active IP Right Grant
- 2013-04-30 EP EP13784744.8A patent/EP2844742B1/en active Active
- 2013-04-30 ES ES13784744T patent/ES2711629T3/es active Active
- 2013-04-30 CN CN201810086091.3A patent/CN108384758B/zh active Active
- 2013-04-30 EP EP18198906.2A patent/EP3447125B1/en active Active
- 2013-04-30 CA CA2871955A patent/CA2871955C/en active Active
- 2013-04-30 ES ES18198906T patent/ES2878724T3/es active Active
- 2013-04-30 CN CN201810720554.7A patent/CN108795875B/zh active Active
- 2013-04-30 JP JP2015510393A patent/JP6411328B2/ja active Active
- 2013-04-30 RU RU2014148136A patent/RU2653761C2/ru active
- 2013-04-30 CN CN201380034582.9A patent/CN104395463B/zh active Active
- 2013-04-30 AU AU2013256424A patent/AU2013256424B2/en active Active
- 2013-04-30 EP EP21158803.3A patent/EP3904503A1/en active Pending
- 2013-04-30 BR BR112014027155-0A patent/BR112014027155B1/pt active IP Right Grant
-
2014
- 2014-10-28 MX MX2019007492A patent/MX2019007492A/es unknown
-
2015
- 2015-08-31 HK HK15108443.9A patent/HK1207882A1/xx unknown
-
2016
- 2016-01-22 US US15/003,968 patent/US9663763B2/en active Active
-
2017
- 2017-04-10 US US15/483,704 patent/US11136549B2/en active Active
-
2018
- 2018-05-15 JP JP2018093635A patent/JP6805204B2/ja active Active
- 2018-10-26 AU AU2018253624A patent/AU2018253624B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014148136A (ru) | Композиции т-клеток с недостаточностью рецепторов т-клеток | |
| MX2019003886A (es) | Receptores de antigenos quimericos para el tratamiento del cancer. | |
| PH12017500918A1 (en) | Antibodies against cd73 and uses thereof | |
| EA201892619A1 (ru) | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 | |
| MY195318A (en) | Multispecific Antibody Constructs | |
| MX2019000643A (es) | Receptores de antigenos quimericos y metodos de uso. | |
| MY195167A (en) | Modified Nucleotide Linkers | |
| NZ725079A (en) | Transgene genetic tags and methods of use | |
| NZ761188A (en) | Antibody molecules to tim-3 and uses thereof | |
| MX2013003681A (es) | Ácidos nucleicos manipulados y métodos de uso de los mismos. | |
| WO2015051199A3 (en) | Modified pseudomonas exotoxin a | |
| EA201270713A1 (ru) | Белки на основе фибронектина с каркасными доменами, которые связывают ил-23 | |
| EA201692359A1 (ru) | Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса | |
| RU2015119517A (ru) | Новый способ лечения инфаркта миокарда с применением фрагмента hmgb1 | |
| MX357391B (es) | Anticuerpos anti-erbb3 y usos de los mismos. | |
| GB201020995D0 (en) | Biological materials and uses thereof | |
| GB0917002D0 (en) | Improved shigella blebs | |
| EA201690600A1 (ru) | Метаболически оптимизированная клеточная культура | |
| MX363819B (es) | Uniones a cdim y sus usos. | |
| MX2019002903A (es) | Receptores de antigeno quimerico que comprenden dominios de tipo iii de fibronectina especificos del bcma y usos de estos. | |
| MX347515B (es) | Agentes que se unen al receptor encrespado y usos de los mismos. | |
| MX2019003427A (es) | Composiciones para cultivo celular y metodos para la produccion de polipeptidos. | |
| WO2016073595A8 (en) | T cells and dendritic cells for polyomavirus therapy | |
| MX2019007248A (es) | Enzimas de polimerizacion para reacciones de secuenciacion. | |
| NZ603196A (en) | Methods of use of soluble cd24 for therapy of rheumatoid arthritis |